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vance. Like all membrane-embedded proteins, their location and orientation are influenced by lipids, which can also impact pro-
tein function via specific interactions. Extensive simulations totaling 0.25 ms reveal a process in which phospholipids from the
membrane’s cytosolic leaflet enter the empty G-protein binding site of an activated b2 adrenergic receptor and form salt-bridge
interactions that inhibit ionic lock formation and prolong active-state residency. Simulations of the receptor embedded in an
anionic membrane show increased lipid binding, providing a molecular mechanism for the experimental observation that anionic
lipids can enhance receptor activity. Conservation of the arginine component of the ionic lock among Rhodopsin-like G-protein-
coupled receptors suggests that intracellular lipid ingression between receptor helices H6 and H7 may be a general mechanism
for active-state stabilization.INTRODUCTIONIntercellular communication is essential for many facets
of multicellular life (1–4). At a conceptual midpoint of all
intercellular communication pathways lies the cell mem-
brane, whose combination of low and high dielectric
lamellae provides a physical barrier to solute passage
(5–8). Proteins embedded within these membranes enable
homeostasis and communication by providing selective
permeability to both matter and information (9–15).
The functional dynamics of membrane proteins are influ-
enced by lipid composition, which controls membrane
bulk properties such as thickness, fluidity, and surface po-
tential, and provisions lipid species that can engage in spe-
cific and functionally relevant lipid-protein interactions
(16–20). These interactions are mediated by membrane pro-
tein residues that are often conserved and, at the cytosolic
interface, most commonly involve arginine (21).
G-protein-coupled receptors (GPCRs) are a class of
transmembrane protein that relay extracellular information
into eukaryotic cells (9,22–25). The human genome con-
tains over 800 different GPCRs, which have evolved to
bind thousands of different chemicals and evoke varied
cellular responses (26). As such, GPCRs play crucial roles
in olfaction, vision, appetite, mood, heart rate, blood pres-
sure, and pain control (27), and are targeted by 30% of
drugs (28).Submitted June 9, 2015, and accepted for publication August 24, 2015.
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0006-3495/15/10/1652/11In a simplified representation, a GPCR exists in either
an active or inactive state. Extracellular ligands called ago-
nists stabilize or induce the receptor’s active states, which
have guanine nucleotide exchange factor activity toward
a cytosolically bound, inactive, guanosine-diphosphate-
containing Gabg protein heterotrimer (29). This guanine
nucleotide exchange factor activity causes the release of
guanosine-diphosphate from the Ga subunit (29), which
then tends to bind guanosine-triphosphate. Ensuing confor-
mational changes in the G-protein lead to dissociation of the
Ga subunit from the Gbg heterodimer, both of which are then
free to initiate downstream signaling pathways (30). Cyto-
solic phosphorylation of the receptor by kinases (31,32) en-
ables arrestin recruitment, additional signaling, and cellular
desensitization to agonist-mediated stimulation via receptor
internalization (33).
The well-studied beta 2 adrenergic receptor (b2AR)
provides an excellent model system for defining the activa-
tion mechanisms available to GPCRs. Sixteen crystal struc-
tures of the b2AR are currently available. Ten of these
structures are inactive and tightly packed at the cytosolic
surface (34–40), with receptor helix 6 (H6) approaching
H3; in the six apparently active structures (41–44), the cyto-
solic end of H6 is splayed outward, facilitating receptor
engagement with a guanine nucleotide-free heterotrimeric
G-protein (41) or a mimetic nanobody (42–44) (see Fig. 1).
Surprisingly, agonist binding does not appear to be suffi-
cient to fully stabilize active states of the b2AR (45,46). All
existing crystallographic structures of this receptor’s active
states are bound to a protein that engages and presumably
stabilizes the cleft between receptor helices H3 and H6http://dx.doi.org/10.1016/j.bpj.2015.08.028
FIGURE 1 Cytosolic view of H6 splaying upon receptor activation. Re-
ceptor helices are shown as cylinders colored by PDB ID. H6 splaying,
quantified by cytosolic H3–H6 separation, is larger for (blue and cyan)
active than (red and orange) inactive crystal structures. To see this figure
in color, go online.
Regulation of GPCR Activity by Lipids 1653(41–44). Even covalent, biochemically active agonist-recep-
tor complexes crystallize in an inactive state (40) unless
cocrystallized with a nanobody that binds at the receptor’s
cytosolic face (44). Molecular simulations corroborate the
fragile nature of the receptor’s active states in the absence
of an intracellular binding partner. Simulations starting
from active states exhibit spontaneous receptor deactivation
on the low microsecond timescale (47,48), even in the pres-
ence of an extracellular agonist (40,48). This deactivation
often involves the formation of a salt bridge between an
arginine in H3 and a glutamic acid in H6 (40,48,49), an ionic
lock that is thought to stabilize inactive states (50). Consis-
tently, inactive conformations of the receptor do not sponta-
neously activate on achievable timescales during unbiased
simulations with (51) or without (49,52,53) agonist. It is
currently unclear how ligand binding generates efficient
signal transduction and whether the binding of downstream
signaling proteins involves induced fit, conformational se-
lection, or both. Nevertheless, recent double electron-elec-
tron resonance and 19F NMR spectroscopy suggest that,
even in the absence of a cytosolic binding protein, agonist
binding induces 15–60% of the receptor’s conformational
ensemble to adopt an active-like state with extensive H6
splaying (46).
Here, we investigate specific interactions of membrane
lipids with the b2AR and provide a mechanism that explains
how phospholipids may act as facultative cofactors to pro-
long the receptor’s residency in active states or activation
intermediates. Specifically, a phospholipid from the mem-brane’s cytosolic leaflet can insert between receptor helices
H6 and H7 and form a salt bridge with the arginine compo-
nent of the ionic lock. This lipid binding occurs much more
frequently in active than inactive receptor states, suggesting
that lipid binding can stabilize active states via conforma-
tional selection. Of importance, we show that anionic lipids
outcompete zwitterionic lipids for arginine binding and may
therefore be even more disruptive to ionic lock formation
and receptor deactivation, consistent with available experi-
mental data.MATERIALS AND METHODS
The simulation system consists of a truncated form of the human b2AR
embedded in a hydrated lipid bilayer comprising zwitterionic POPC or
anionic POPG (Fig. S1 in the Supporting Material). Simulations use a
wild-type receptor sequence that is based on the resolved residues in the
crystal structure of a mutant construct that maintains the wild-type profile
of guanosine-triphosphategS binding in apo, agonist-(isoproterenol), and
inverse-agonist-(ICI-118551) bound states (Protein Data Bank (PDB) ID:
4GBR) (35). This sequence is truncated at the N- and C-termini and in intra-
cellular loop 3. Specifically, in comparison to the receptor’s wild-type
sequence (UniProt ID: P07550), the sequence in our simulations is
D(M1-D29), D(S236-K263), and D(L342-L412). Residues D2.50 and
E3.41 are protonated and the C341 palmitoyl group (54) is not included.
Residue identifiers follow the Ballesteros and Weinstein format: N.M,
where N is the transmembrane helix number andM equals 50 plus the offset
from the most conserved residue in that helix (55).
Molecular dynamics simulations are conducted with a single-precision
compilation of version 4.6.1 of the GROMACS simulation package (56).
Macromolecules are modeled by the CHARMM 22/27 protein force field
(57) with grid-based energy correction maps (58), and the CHARMM 36
lipid force field (59) as implemented in GROMACS (60,61). This lipid
force field reproduces experimental bulk properties of POPG (62). The wa-
ter model is TIP3P (63) with CHARMM modifications (57). Water mole-
cules are rigidified with SETTLE (64) and bond lengths in protein and
lipid are constrained with P-LINCS (65) using sixth-order coupling and a
single iteration. Lennard-Jones interactions are evaluated using an atom-
based cutoff, gradually switching off the potential energies of interactions
between 0.8 and 1.2 nm. Coulomb interactions are calculated using the
smooth particle-mesh Ewald method (66,67) with a Fourier grid spacing
of 0.12 nm. Simulation in the NpT ensemble is achieved by semiisotropic
coupling to Berendsen barostats (68) at 1 bar with coupling constants of
4 ps and temperature coupling the simulation system using velocity Lange-
vin dynamics (69) at 310 K with a coupling constant of 1 ps. The integration
time step is 2 fs. The nonbonded pairlist is updated every 20 fs. Further de-
tails are provided in the Supporting Material.RESULTS
We conduct replicate simulations of active conformations
of the apo form of the human b2AR embedded in a hydrated
zwitterionic lipid bilayer (Fig. S1). Initial receptor conforma-
tions are drawn from crystal structures in which the b2AR
is bound to an agonist and either a G-protein (41) or a
G-protein-mimicking nanobody (42), which are hereafter
referred to as G-protein- and nanobody-derived structures,
respectively. To obtain a statistical measure of receptor
dynamics, we conduct 52 1-ms simulations of each receptor
conformation.Biophysical Journal 109(8) 1652–1662
1654 Neale et al.Receptor deactivation
We use three metrics to quantify the extent of receptor deac-
tivation in our simulations: collapse of the cytosolic binding
pocket, inward swinging of H6 toward H3, and formation of
the ionic lock (Fig. 2, A–C). These measures are strongly
correlated, with absolute values of pairwise Pearson correla-
tion coefficientsR0.8 (Fig S2). Interestingly, the nanobody-
derived structure deactivates 5–10 times more often than the
G-protein-derived structure (Table 1 and Fig. 2, D and E).
During this deactivation process, ionic lock formation and
occlusion of the receptor’s cytosolic binding pocket are in
some cases reversible (Fig. S3, A and C). However, once
H6 swings inward to sample dH3–H6 values <0.8 nm the re-
ceptor remains in the inactive conformational basin for the
remainder of the simulation (Fig. S3 B).
Even when the apo receptor is in an active state with
H6 splayed outward at least as much as it is in the G-pro-
tein-derived structure (dH3–H6R1.54 nm; Fig. 1), protein
breathing motions including side-chain flexibility, loop rear-
rangement, and movement of H5 toward H3 lead the recep-
tor to take up some of the space occupied by the G-protein in
its crystallographic pose (41), hereafter referred to as the
G-protein volume. In simulations of the G-protein-derived
structure, the average G-protein volume occluded by the re-
ceptor when dH3–H6R 1.54 nm is 0.195 0.01 nm
3, or about
eight heavy atoms (Fig. 2 D). Therefore, our simulations
indicate that G-protein binding requires some form of
induced fit or conformational selection even when H6 is
splayed outward.FIGURE 2 Receptor deactivation. (A–C) Cytosolic view of representative stru
the receptor for each of the following deactivation metrics: (A) volumetric clash b
of a Ga protein based on postsimulation modeling, Vclash (see Supporting Materia
by the distance between (yellow spheres) Ca atoms of R3.50 and L6.34, dH3–H6
distance between (sticks) R3.50 and E6.30, dlock (also depicted in Movie S1). (D
red line) G-protein- and (dashed blue line) nanobody-derived structures. Dotted
simulations when dH3–H6 R 1.54 nm, the crystallographic active-state displac
denote abscissa values for selected crystal structures. To see this figure in color
Biophysical Journal 109(8) 1652–1662To assess the generality of these results, the entire set
of simulations is repeated with the AMBER99SB-ILDN
protein force field (70) and the Stockholm lipid parameters
(71). These AMBER simulations corroborate our conclu-
sion that the nanobody-derived structure deactivates more
rapidly than the G-protein-derived structure (Supporting
Results, Table S2, and Fig. S7, B–D).Lipid binding to the receptor’s cytosolic pocket
The side chain of the R3.50 component of the ionic lock
is located in the core of the receptor’s binding pocket in
all available crystal structures of the b2AR. Surprisingly,
our simulations indicate that a phospholipid can insert be-
tween the cytosolic ends of receptor helices H6 and H7
and form a salt bridge with the guanidino moiety of this
arginine residue when the receptor is in an active state
(Fig. 3 A). Conversely, receptor deactivation tends to
bring H6 toward H7 and exclude lipids from the G-protein
binding pocket (Fig. 3 B). Lipid binding is quantified in
Table 2.
The specific binding of membrane lipids to R3.50 occurs
more often when H6 is splayed outward (Figs. 3 C and S4,
A and B) and when the ionic lock is broken (Figs. 3 D
and S4, C and D). The incompatibility of lipid binding
with H6 closure and ionic lock formation suggests that
the ingression of a lipid from the bilayer’s cytosolic
leaflet may stabilize the receptor’s active state and
compete with E6.30 for interaction with R3.50. Thisctures from simulations depicting (left) active and (right) inactive states of
etween the (orange) simulated apo receptor and the (black) C-terminal helix
ls and Methods); (B) approach of the cytosolic ends of H3 and H6 measured
; and (C) formation of the ionic lock as measured by the minimum Nh-Oε
–F) Probability histograms of deactivation metrics in simulations of (solid
gray lines in parts (D) and (F) represent the data from G-protein-derived
ement. Vertical bars represent standard error. Arrows and PDB identifiers
, go online.
TABLE 1 Receptor deactivation
Crystallized
with
% of Simulations
Exhibiting % of Time
Active State
Half-Life (ms)
H3–H6
Closurea Ionic Lockb Closeda Lockedb
G-protein 255 2 125 0 7 5 1 2 5 1 2.95 0.3
Nanobody 835 2 815 4 61 5 3 46 5 1 0.65 0.2
aCa distance between R3.50 and L6.34, dH3–H6 < 0.94 nm.
bMinimum Nh-Oε distance between R3.50 and E6.30, dlock < 0.35 nm.
Regulation of GPCR Activity by Lipids 1655specific lipid binding is also more common in simulations
of G-protein- than nanobody-derived structures (Table 2
and Fig. 3 E), pointing to a possible molecular basis for
the different stability and lipid binding properties of these
two structures in our simulations. Specifically, in the nano-
body-derived structure, R3.50 extends toward the cytosol.
Conversely, in the G-protein-derived structure, R3.50
extends toward H6/H7 where this cation may act to preor-
ganize annular lipids for entry into the G-protein binding
pocket.
In five of our simulations, a lipid from the cytosolic
leaflet moves entirely into the G-protein binding pocket,
sporadically maintaining salt-bridge interactions with
R3.50 and remaining in the binding pocket until the sim-
ulations are terminated (Fig. S5). This complete lipid entry
is only observed in simulations of the G-protein-derived
structure. Even though a lipid remains in the receptor’sFIGURE 3 Zwitterionic lipid binding to the R3.50 component of the ionic lock
inactive, lipid unbound states. Ca atoms used in evaluation of dH3–H6 are shown
dlock for (solid black line) lipid-unbound and (dashed gray line) lipid-bound state
and a lipid, dR3.50-lipid, for simulations of (solid red line) G-protein- and (dashed
dR3.50-lipid vs. dH3–H6 and dlock are presented in Fig. S4. To see this figure in cobinding pocket for a total of 2.96 ms in these five
simulations, the R3.50-lipid oxygen binding condition
(dR3.50-lipid < 0.35 nm) is only met for 1.12 ms due to
the high degree of mobility experienced by a bound zwit-
terionic lipid (Movie S3). Taking the full duration of these
lipid invasion events into consideration, zwitterionic lipids
bind R3.50 and/or enter the receptor’s binding pocket 6%
of the time across all 52 simulations initiated from this re-
ceptor structure. Extension of two of these simulations to
14 and 3 ms clarifies that this is a stable or metastable
interaction in which the lipid remains in the receptor’s
G-protein binding pocket and the receptor remains active
(Figs. 4 and S6).
AMBER simulations corroborate the specific binding of
a lipid to the R3.50 component of the ionic lock (Table S3
and Fig. S7 A). They also support our conclusions that
lipids bind more extensively to the G-protein- than to the
nanobody-derived structure (Table S3 and Fig. S7 E) and
that lipid entry to the receptor’s cytosolic binding occurs
more often when H6 is splayed outward (Fig. S7 F) and
when the ionic lock is broken (Fig. S7 G). However,
compared to the CHARMM simulations, lipid binding to
R3.50 is at least an order of magnitude less stable in
AMBER simulations (Tables 2 and S3 and Figs. 3 E and
S7 E), which also do not feature any of the complete lipid
insertion events that we observe in five of the CHARMM
simulations (Figs. 4, S5, and S6). The source of this
discrepancy is unclear.. (A and B) Representative conformations of (A) active, lipid bound and (B)
as yellow spheres. (C and D) Probability histograms of (C) dH3–H6 and (D)
s. (E) Probability histograms of the minimum Nh-O distance between R3.50
blue line) nanobody-derived structures. Probability density maps depicting
lor, go online.
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TABLE 2 Zwitterionic lipid binding to R3.50
Crystallized with
No. of Distinct Binding
Eventsa,b % of Lipid-Bound R3.50b
G-protein 37 35 1
Nanobody 10 0.25 0.02
aNot counting rebinding of a previously bound lipid.
bMinimum Nh-O distance between R3.50 and a lipid, dR3.50-lipid< 0.35 nm.
1656 Neale et al.Anionic lipids bind R3.50 more frequently
The specific interaction between a lipid and R3.50 suggests
that a cytosolically bound phospholipid may be able to tran-FIGURE 4 Complete invasion of the receptor’s cytosolic binding pocket
by a zwitterionic lipid. (A) Probability density map of (black, labeled P) the
phosphorus atom of the bound phospholipid and (cyan, labeled 1–7) trans-
membrane helices viewed from the cytosol in a single 14-ms simulation
initiated from the G-protein-derived structure. Each helix is represented
by four Ca atoms near the headgroup region of the bilayer’s cytosolic leaflet
(see Supporting Materials and Methods). (B) Time trajectories of H6 splay-
ing, dH3–H6, ionic lock formation, dlock, and R3.50 binding for the single
identified lipid, dR3.50-lipid. Ordinate units are nm. (C–F) Cytosolic view
of representative conformations from time points noted in (B). This simu-
lation is depicted in Movie S3. Corresponding data for another 3-ms simu-
lation in which a lipid dissociated from the receptor’s annular lipids and
moved completely into the receptor’s cytosolic binding pocket are provided
in Fig. S6. To see this figure in color, go online.
Biophysical Journal 109(8) 1652–1662siently stabilize active states of the receptor. If this is the
case, charge complementarity may lead anionic lipids to
occupy the receptor’s cytosolic binding pocket and stabilize
active receptor states with greater frequency than the zwit-
terionic lipids used in the aforementioned simulations.
Indeed, free energy profiles characterizing the interaction
between analogs of amino acid side chains and lipid head-
groups indicate that arginine binding strength follows the
progression glutamate/aspartate > anionic lipids > zwitter-
ionic lipids (Fig. S8). Therefore, we conduct 52 1-ms sim-
ulations of the apo b2AR embedded in an anionic
phosphatidylglycerol bilayer using the G-protein-derived
receptor structure.
As hypothesized, salt-bridge interactions between lipids
and R3.50 are more common with anionic lipids (Table 3
and Fig. S9 D) than with zwitterionic lipids (Table 2 and
Fig. 3 E). Anionic lipid binding is also largely incompatible
with complete H6 closure (Fig. S9 E) or ionic lock forma-
tion (Fig. S9 F). Moreover, anionic lipids enhance the stabil-
ity of the receptor’s active state, increasing its half-life by a
factor of three (Tables 1 and 3), although it is unclear if this
active-state stabilization is entirely due to R3.50-lipid inter-
actions. Complete lipid entry to the receptor’s binding
pocket occurs in two of these simulations (not shown).
Anionic lipid binding is depicted in Movie S4.
Both lipid types most frequently interact with R3.50 by
way of a salt bridge between the side chain of this receptor
arginine and the free oxygen atoms in the lipid’s phosphate
group, although other lipid oxygen atoms also contribute to
this interaction, especially those in the headgroup glycerol
moiety of phosphatidylglycerol lipids (Fig. 5).
Of importance, lipid binding at R3.50 does not neces-
sarily preclude G-protein binding. Bound zwitterionic
and anionic lipids occupy, on average, 0.11 5 0.02 and
0.055 5 0.002 nm3 of the G-protein volume, respectively
(Fig. 6 A). These volumes correspond to four and two heavy
atoms, respectively, and are substantially less than the
G-protein volume occupied by the receptor itself when
dH3–H6 R 1.54 nm (Fig. 2 D). Protrusion of receptor and
lipid into the G-protein binding volume is depicted in
Fig. 6, B and C. Just as the receptor’s conformation likely
responds to the presence of a G-protein, a receptor-bound
lipid may reorganize or be extruded back into the membrane
upon receptor-G-protein interaction, especially since the
bound lipid can be quite dynamic (Figs. 4 and S4 and
Movies S2 and S3). However, if the bound lipid interferes
with G-protein binding, the net effect of lipid binding on
receptor activity is then given by the relationship between
stabilization of the receptor’s active state and G-protein
interference.DISCUSSION
Based on a vast number of simulations (N ¼ 260 totaling
254 ms), we consistently identify spontaneous invasion of
TABLE 3 Lipid binding and receptor deactivation in simulations with anionic lipids
No. of Distinct Lipid
Binding Eventsa,b
% of Lipid-Bound
R3.50b (%)
% of Simulations Exhibiting % of Time
Active State
Half-Life (ms)H3–H6 Closurec Ionic Lockd Closedc Lockedd
83 145 1 12 5 0 215 2 45 2 25 1 9.45 1.6
aNot counting rebinding of a previously bound lipid.
bMinimum Nh-O distance between R3.50 and a lipid, dR3.50-lipid < 0.35 nm.
cCa distance between R3.50 and L6.34, dH3–H6 < 0.94 nm.
dMinimum Nh-Oε distance between R3.50 and E6.30, dlock < 0.35 nm.
Regulation of GPCR Activity by Lipids 1657the b2AR’s cytosolic binding pocket by membrane lipids,
which bind the R3.50 component of the ionic lock by insert-
ing their headgroup between receptor helices H6 and H7
(Figs. 3, 4, and 6, C andD) and stabilize the receptor’s active
states (Figs. 3, C and D, S4, and S9, E and F). This specific
lipid binding is reminiscent of the pathway by which the
sn-2-arachidonoylglycerol ligand has been predicted to
bind the cannabinoid type 2 (CB2) receptor (72), though
in this case occurring in the cytosolic membrane leaflet.
Similarly, experimental studies highlight the differential in-
fluence of lipid- and detergent-based environments on the
equilibrium between open and closed states of potassium
channel KscA (73), the stability of CC-chemokine receptor
5 (74), the ligand binding strength (75) and activation dy-
namics (76) of the b2AR, and the activity of rhodopsin
(77–80).
Additional simulations show that anionic lipids enter the
receptor’s binding pocket and interact with R3.50 more
readily than zwitterionic lipids (Tables 2 and 3 and
Fig. 5), providing a detailed molecular mechanism for the
experimental finding that anionic lipids can enhance recep-
tor activity. Specifically, Inagaki et al. (81) showed that the
addition of phosphatidylglycerol to nanodisks containing rat
neurotensin receptor 1 increases the rate of nucleotide ex-
change at Gqa much more dramatically than it increases
the receptor’s affinity for the peptide agonist neurotensin,
even in nanodisks with purely anionic lipids. Likewise,
Kimura et al. (82) showed that phosphatidylserine enhancesFIGURE 5 Lipidic oxygen atoms involved in R3.50 binding. (Left) zwit-
terionic PC and (right) anionic PG lipids are shown with oxygen atom
volume proportional to time spent interacting with an Nh atom of R3.50
(d < 0.35 nm) in simulations of the G-protein-derived crystal structure.
Numbers represent the percentage of time for which this binding criterion
is met (oxygen atoms without numbers are <0.5%). To see this figure in
color, go online.the activity of the human CB2 receptor in reconstituted lipo-
somes, although in this case receptor activity is reduced at
very high concentrations of anionic lipids (1:4 zwitter-
ionic/anionic). Rhodopsin activation is also enhanced in
the presence of phosphatidylserine (83), though the pH
dependence of rhodopsin’s activation (84) suggests that
anionic lipids may be acting indirectly via proton enrich-
ment. Finally, G-protein-coupled receptor kinases, which
may occupy the receptor’s G-protein binding pocket (85),
phosphorylate activated receptors with greater efficacy in
the presence of anionic lipids (86,87).
The simulations outlined in this article are initiated from
active conformations of the receptor. Therefore, these simu-
lations assess the ability of lipids to stabilize, but not induce,
active states, and the proposed mechanism requires that
active-like splaying of H6 occurs in agonist-bound receptors
before their interaction with a downstream signaling protein
or mimetic nanobody. Crystal structures of this receptor are
very similar in complex with agonists (40) and inverse ago-
nists (34,36) and to date only G-protein- and mimetic nano-
body-stabilized crystals capture the receptor’s active state
(41–44). Nevertheless, in solution, agonist binding alone
(in the absence of a G-protein or nanobody) appears to in-
crease the mobility of the intracellular end of H6 (45,88).
This is the same region of the receptor that undergoes a
large-scale conformational change upon activation and pro-
tein binding at the receptor’s cytosolic face (Fig. 1) and that
must separate from H7 to permit lipid entry (Figs. 3, A and
B, and 6, C and D). Specifically, the agonist BI-167107
shifts the receptor’s conformational ensemble toward a pre-
sumed activation intermediate in which the dynamics of a
cytosolic region of H6 including C6.27 is increased (45).
Likewise, the agonist isoproterenol causes L6.34-T6.45 to
become less protected from deuterium/hydrogen exchange,
consistent with increased structural plasticity (88). More-
over, both of these agonists alone lead the b2AR to sample
conformations in which the distance between L6.28 and
N4.40 reported by double electron-electron resonance spec-
troscopy increases by R0.8 nm (46). Although 19F NMR
spectroscopy indicates that this H6 splaying may represent
an on-pathway activation intermediate with distinct confor-
mational features from fully active G-protein- or nanobody-
bound receptor states (46), the agonist-driven increase in
mobility (45,88) and splaying (46) of the cytosolic end of
H6 supports the possibility that the specific lipid bindingBiophysical Journal 109(8) 1652–1662
FIGURE 6 Lipid and G-protein binding. (A) Probability histogram of
volume overlap between a receptor-bound lipid and the C-terminal helix
Biophysical Journal 109(8) 1652–1662
1658 Neale et al.described in this article may occur before receptor interac-
tion with a G-protein. The hypothesized mechanism by
which a lipid may stabilize a receptor’s active state via
conformational selection is depicted schematically in Fig. 7.
There is a precedent for the specific formation of a salt
bridge between a lipid headgroup and an arginine residue
in a GPCR, albeit at the receptor’s extracellular face. In
the orthosteric site of the sphingosine 1-phosphate 1 recep-
tor, the phosphate group of an antagonist sphingolipid
mimic is coordinated by an arginine residue (89), whose
mutation reduces the potency of a variety of agonists (90).
To our knowledge, reports of specific nonligand lipid/
fatty acid binding sites on GPCRs have thus far been
restricted to the receptor’s periphery (34,37,91–96), with
the exception of extracellular invasion of an oleic acid
acyl chain between H1 and H7 of the adenosine A2A recep-
tor (95). In simulations, the cytosolic H6/H7 interface
of inactive rhodopsin forms tight interactions with docosa-
hexanoic acid, stearic acid, and cholesterol (96) and
docosahexanoic penetrates rhodopsin’s helical interfaces
nonspecifically (97).
Localization of R3.50 in the membrane’s cytosolic head-
group plane favorably situates this residue to alternately
bind a lipid or form the ionic lock. The specific binding
between a lipid from the membrane’s cytosolic leaflet and
R3.50 appears to be incompatible with the receptor’s
completely inactive states (Figs. 3, C and D, and S9, E
and F), and may act as a metaphorical foot in the door of
the activated receptor as it awaits favorable interaction
with downstream signaling proteins including G-proteins,
G-protein-coupled receptor kinases, and arrestins (98).
This lipid-protein binding may also affect or underlie a re-
ceptor’s ability to differentially couple with various G-pro-
tein families by regulating the size of the receptor’s
cytosolic binding pocket (99). Furthermore, the likelihood
of this specific protein-lipid interaction depends on mem-
brane composition (Fig. 5), which varies with cell type
(100,101), cell-cycle stage (102), disease (101,103), diet
(104), acquired drug resistance (105), and localization in
membrane microdomains (106), thus providing novel ave-
nues for receptor regulation as generally proposed by Ina-
gaki et al. (81) and defined mechanistically in this work.
Finally, the overwhelming conservation of R3.50 across
type-AGPCRs (107) suggests that the hypothesis developedof a Ga protein based on postsimulation modeling, Vclash-lipid. Data are ob-
tained from simulations of the G-protein-derived structure with (solid black
line) zwitterionic, PC, and (dashed red line) anionic, PG, lipids. The dotted
gray line represents the PC data after omitting the five simulations in which
the bound lipid completely invaded the receptor’s binding pocket (Fig. S5).
Distributions of Vclash vs. Vclash-lipid are provided in Fig. S10. (B and C) Two
cytosolic depictions of the same representative snapshot from simulations
in which an anionic lipid is bound at R3.50 and the values of Vclash and
Vclash-lipid are similar to the mean values for lipid-bound states in these sim-
ulations (values for this snapshot are 0.2 and 0.05 nm3, respectively). To see
this figure in color, go online.
FIGURE 7 Proposed role of lipid binding in putative GPCR activation
pathways. Extracellular agonist binding enhances the mobility of the cyto-
solic end of receptor helix H6. Transient outward splaying of this helix per-
mits lipid binding to the R3.50 component of the ionic lock, stabilizing the
receptor’s active state before its interaction with a downstream signaling
protein. This lipid binding is more common with anionic lipids, which pro-
vide further stabilization. Receptor helices H6 and H7 are shown in (I) inac-
tive, (A) active, or (I*) inactive intermediate states as they interact with
(yellow star) agonist, (red and blue circle and sticks) lipid, and (green
blob) a cytosolic binding protein such as a G-protein. To see this figure
in color, go online.
Regulation of GPCR Activity by Lipids 1659in this article for the b2AR may be broadly relevant across
this pharmaceutically important class of membrane proteins.SUPPORTING MATERIAL
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